Home > Insider Trading > Filing (0001209191-15-086235)

Filing Details

Accession Number:: 0001209191-15-086235
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-12-18 21:39:34
Reporting Period:: 2014-09-19

Filing Date:: 2015-12-18
Accepted Time:: 2015-12-18 21:39:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1419554	Bone Biologics Corp	NONE	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	421743430

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1655452	Chia B Soo	C/O Bone Biologics Corporation 321 Columbus Avenue Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-09-19	1,000,000	$0.00	1,000,000	No	4	J	Direct
Common Stock	Acquisiton	2015-09-19	31,646	$0.00	1,031,646	No	4	A	Direct
Common Stock	Disposition	2015-10-09	52,744	$1.58	978,902	No	4	S	Direct
Common Stock	Disposition	2015-10-22	2,000,000	$0.00	0	No	5	G	Indirect	By Spouse
Common Stock	Acquisiton	2015-10-22	2,000,000	$0.00	2,978,902	No	5	G	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Direct
No	4	A	Direct
No	4	S	Direct
No	5	G	Indirect	By Spouse
No	5	G	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (Right to Buy)	Acquisiton	2014-09-19	119,318	$0.00	119,318	$0.44
Common Stock	Common Stock (Right to Acquire)	Acquisiton	2015-10-02	384,615	$0.00	384,615	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
119,318		2024-09-19	No	4	J	Direct
384,615			No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,000,000	Indirect	By Spouse

Footnotes

Represents shares of Common Stock of the Issuer issued pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 19, 2014 by and among AFH Acquisition X, Inc., Bone Biologics, Inc. and Bone Biologics Acquisition Corp. Pursuant to the terms of the Merger Agreement each share of Common Stock of Bone Biologics, Inc. was converted into the same number of shares of the Issuer's Common Stock.
These shares are owned by Kang Ting. Dr. Ting is the spouse of the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Does not include 384,615.33 shares of Common Stock issuable to Dr. Ting on the earlier of September 24, 2018 and the occurrence of certain events described in a letter agreement by and between the Issuer and the Reporting Person dated September 24, 2015 and attached as Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on October 8, 2015.
These shares were acquired by the Reporting Person pursuant to Reporting Person's non-employee director offer letter with the Issuer.
These shares were sold by the Reporting Person in a private transaction.
This transaction involved a gift of the shares of Common Stock owned by Dr. Ting to the Reporting Person.
On February 4, 2010, the Reporting Person acquired a warrant to purchase 119,318 shares of Common Stock of Bone Biologics, Inc.at an exercise price of $0.44 per share. Pursuant to the Merger Agreement, this warrant was converted into a warrant to purchase 119,318 shares of the Issuer's Common Stock at a per share exercise price of $0.44. The warrant is fully vested and exercisable.
Immediately exercisable.
Issuable to the Reporting Person on the earlier of September 24, 2018 and the occurrence of certain events described in a letter agreement by and between the Issuer and the Reporting Person dated September 24, 2015 and attached as Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on October 8, 2015.